Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02545959
Other study ID # CHPAU2014/01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 30, 2015
Est. completion date September 2, 2019

Study information

Verified date April 2019
Source Centre Hospitalier de PAU
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of investigators is to study the kinetics of action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets in progressive MS patients. Various markers of central nervous system inflammation (osteopontin, Tumor Necrosis Factor α, IgG secretion) and neurodegeneration (neurofilament) are studied at multiple time-points, assuming that a definitive action upon CSF biological targets would be strongly predictive of a delayed clinical action.


Description:

• Background : Multiple sclerosis (MS) is the most frequent inflammatory disorder leading to impairment in young people. Although many drugs are now available to treat the early relapsing-remitting phase of MS (RR-MS), impairment is mostly linked to the secondary progressive phase of MS. Since no treatment proved to efficiently prevent or cure this progressive phase, treating this phase remains challenging. In fact, progressive phase is associated with a fence-ringed intrathecal compartmentalization of inflammation, leading to the unavailability of most immunosuppressive drugs. As a consequence, investigators here propose to shift the therapeutic paradigm in MS to a new paradigm based on intrathecal infusion of monoclonal antibodies (mAb) aimed at eradicate intrathecal inflammation. Rituximab is a mAb targeting CD20+ B-lymphocytes. Positive results in RR-MS were obtained after blood infusion of rituximab, but results were negative in progressive MS, probably due to the very low penetration of the blood brain barrier. Since intrathecal rituximab is already used in central nervous system (CNS) lymphomas, investigators propose to use it this way in progressive MS.

• Detailed description : An optimal dosage of rituximab for intrathecal infusion was choose using data already obtained in CNS lymphoma, acknowledging that 20mg offers the higher dosage with good tolerance profile. In order to isolate rituximab effect, a control group is treated by steroids since steroids are required before rituximab infusion. Moreover, B-lymphocytes depletion in CSF will probably be transient, as it is when rituximab is infused in blood. Assuming that CSF B-cells repopulation may be facilitated by peripheral B-cells, a group was assigned to receive also blood infusion of rituximab. CSF will be examined at multiple time points to assess the time frame of biological effect obtained in CSF.

Three groups of 4 patients are treated at day 0 :

1. Control group : receive a single pulse of intravenous (IV) methylprednisolone (120mg) ;

2. Rituximab intrathecal (IT) group : receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect) ;

3. Rituximab IT + IV group : receive same as previous and IV rituximab (375mg/m2) the same day.

CSF and blood will be drawn for study at day 0 (before treatment), day 4, day 21 and day 180. B- lymphocytes monitoring in blood will be also be done at day 365. A detailed clinical monitoring (walking time, nine hole peg test, Expanded Disability Status Score (EDSS), Symbol Digit Modalities Test (SDMT), fatigue intensity scale) will be done at each time point from day 0 to 365, assessing tolerance and clinical effect. MRI will be done at screening, months 6 and 12.

- Primary outcome : Change from baseline in Osteopontin level in CSF at day 4. CSF level is expected to normalize.

- Secondary outcomes: Biological outcomes in CSF (IgG synthesis, Tumor Necrosis Factor α, neurofilament) at day 4; delay to regain pre-therapeutic levels of biological targets in CSF (day 21, day 180) ; clinical data (walking time, nine hole peg test, Expanded Disability Status Score (EDSS), Symbol Digit Modalities Test (SDMT), fatigue intensity scale) at each time point, and brain MRI volumetry at day 180 and day 365.

- Study design : monocentric prospective randomized open clinical trial (phase II).

- Eligibility criteria:

Inclusion criteria:

- Age ≥45 years,

- male or female ;

- Secondary or primary progressive MS, in progressive phase since >2 years ;

- EDSS ≥6.0 ;

- Absence of alternative therapy.

Exclusion criteria:

- Relapsing-remitting phase of MS;

- Contraindication to MRI, lumbar puncture, Trendelenburg position ;

- Active infection or immunosuppressive state or treatment (actual or less than 6 months);

- Earlier treatment with rituximab;

- Dementia or severe psychiatric disorder.

- Arm number or label and arm type :

experimental = Rituximab IT and Rituximab IT + IV groups ; comparator = Control group (methylprednisolone).

- Interventions : Three groups of 4 patients are treated at day 0 : 1) Control group : receive a single pulse of IV methylprednisolone (120mg) ; 2) Rituximab IT group : receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect) ; 3) Rituximab IT + IV group : receive same as previous and IV rituximab (375mg/m2) the same day.

- Number of subjects : 4 per group, with a total of 12 patients.

- Statistical analysis : target sample size was estimated based on an expected outcome of complete clearance of intrathecal inflammation from CNS compartment, which expected to normalize biological markers of CSF inflammation. The estimated size was 6.8 in treatment group and 3.4 in control group. We decided to include respectively 8 and 4 patients in treatment and control groups. Analyses will be performed at the 0.05 global level of significance, risk alpha = 0.05 and risk beta = 0.10. We will use the SAS 9.1.3 software.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date September 2, 2019
Est. primary completion date February 22, 2019
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria:

- Age =45 years, male or female ;

- Secondary or primary progressive MS, in progressive phase since >2 years ;

- EDSS =6.0 ;

- Absence of alternative therapy.

Exclusion Criteria:

- Relapsing-remitting phase of MS;

- Contraindication to MRI, lumbar puncture, Trendelenburg position ;

- Active infection or immunosuppressive state or treatment (actual or less than 6 months);

- Earlier treatment with rituximab;

- Dementia or severe psychiatric disorder.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rituximab IT
CSF injection of intrathecal rituximab (20mg)
methylprednisolone IV
blood infusion of methylprednisolone IV (120mg)
Rituximab IV
Blood infusion of rituximab (375mg/m2)

Locations

Country Name City State
France Centre hospitalier F. Mitterrand (CH Pau) Pau

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier de PAU University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

References & Publications (2)

Bonnan M, Ferrari S, Bertandeau E, Demasles S, Krim E, Miquel M, Barroso B. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials. Curr Drug Targets. 2014;15(13):1205-14. Review. — View Citation

Bonnan M. Intrathecal immune reset in multiple sclerosis: exploring a new concept. Med Hypotheses. 2014 Mar;82(3):300-9. doi: 10.1016/j.mehy.2013.12.015. Epub 2013 Dec 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change in clinical parameters Subjective appreciation and multiple clinical scales (walking time, nine hole peg test, EDSS, SDMT, Fatigue Intensity Scale) day 4, day 21, day 180, day 365
Other Brain volume atrophy Percent change in total brain volume (SIENA) day 180, day 365
Primary Change in osteopontin level in CSF at day 4, day 21, day 180
Secondary Change in Tumor Necrosis Factor alpha level in CSF day 4, day 21, day 180
Secondary Change in IgG synthesis in CSF day 4, day 21, day 180
Secondary Change in neurofilament level in CSF day 4, day 21, day 180
See also
  Status Clinical Trial Phase
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT03222375 - SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT03336645 - Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan Phase 3
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Active, not recruiting NCT02284126 - Topical Vancomycin for Neurosurgery Wound Prophylaxis Phase 3
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT00739518 - Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams N/A
Recruiting NCT03678194 - Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application N/A
Recruiting NCT04698421 - Collection of Biological Samples From Patients With Rare Neurological Diseases